This product is freeze dried. All water molecules have been removed.
Every lot is tried & tested in a relevant biological assay.
Aiken, S.P. et al. (2012) Br. J. Pharmacol. 115, 1163.
Alomone Labs Linopirdine inhibits KCNQ2/KCNQ3 channels expressed in Xenopus oocytes.A. Time course of KCNQ2/KCNQ3 maximal current amplitude, elicited by 700 ms voltage step from holding potential of -100 mV to -20 mV, delivered every 10 seconds. Application of 300 µM Linopirdine (#L-155) inhibits the KCNQ2/KCNQ3 current in a reversible manner (indicated by the horizontal bar). B. Representative current traces before and during application of 300 µM Linopirdine as indicated.
KCNQ2 (KV7.2) and KCNQ3 (KV7.3) are voltage-gated K+ channel subunits that underlie the neuronal M current1. Linopirdine, a putative cognition enhancing drug, increases acetylcholine (ACh) release in rat brain tissue and improves performance in animal models of learning and memory. In addition to ACh, Linopirdine has been shown to enhance the in vitro release of dopamine and 5-hydroxytryptamine (5-HT), and, to a lesser extent, γ-aminobutyric acid and glutamate2. The enhanced release of one or more neurotransmitters may account for the activity linopirdine displays in behavioral models of learning and memory3. The mechanism whereby linopirdine enhances acetylcholine release has been proposed to involve inhibition of the M-type K+ current (IM). Linopirdine is selective for IM with an IC50 value of 2.4 μM2.
Linopirdine (#L-155) is a highly pure, synthetic, and biologically active compound.